Point of Care Infectious Disease Testing Market – By Product, By Technology, By Application, By End Use - Global Forecast, 2024 – 2032

Point of Care Infectious Disease Testing Market Size

The global Point of care infectious disease testing market size was valued at around USD 3.2 billion in 2023 and is estimated to grow at 6.9% CAGR from 2024 to 2032. Point-of-care (POC) infectious disease testing refers to diagnostic tests conducted at or near the site of patient care, rather than in centralized laboratories. These tests are designed to deliver rapid, on-the-spot results, allowing for immediate clinical decisions.
 

The increasing global burden of infectious diseases is a key driver of growth in the point-of-care (POC) infectious disease testing market. With the emergence of new infectious pathogens, the re-emergence of previously controlled diseases, and the growing threat of antimicrobial resistance, rapid and accurate diagnostics are critical for timely intervention. Diseases such as HIV, hepatitis, influenza, and tuberculosis continue to affect millions worldwide.
 

For instance, in 2022, the World Health Organization (WHO) estimated that 10.6 million people globally contracted tuberculosis (TB), including 5.8 million men, 3.5 million women, and 1.3 million children. These figures highlight the widespread impact of the disease across various demographics. Moreover, the recent COVID-19 pandemic further underscored the urgent need for accessible testing solutions. As the spread of infectious diseases remains a significant public health challenge, the demand for POC testing has surged due to its ability to deliver fast, reliable results, enabling timely treatment and containment efforts.
 

Furthermore, technological innovations are driving growth in the point-of-care infectious disease testing market. Advances such as device miniaturization, digital platform integration, and the development of rapid, accurate molecular testing have improved ease of use, portability, and turnaround times. These improvements, particularly in automated devices with real-time data sharing, make point-of-care testing more efficient and widely adopted, especially in remote and resource-limited areas.
 

Point of Care Infectious Disease Testing Market Trends

• Increased awareness about the benefits of early detection and management of infectious diseases has contributed to the growth of the POC testing market. With more education on the importance of timely diagnosis, particularly for contagious diseases, there has been a rise in demand for accessible and rapid testing solutions.
   
• Campaigns led by governments, non-governmental organizations, and healthcare providers focus on promoting self-testing and the convenience of POC diagnostics for diseases such as HIV and influenza.
   
• Therefore, the growing consumer interest in health monitoring, combined with an increased focus on preventative care, stimulates the adoption of POC testing. This provides immediate results and helps reduce the spread of infections.
   

Point of Care Infectious Disease Testing Market Analysis

Based on product, the market is divided into instruments and kits & reagents. The kits and reagents segment dominated the market with the largest revenue of USD 2.5 billion in 2023 and is expected to grow at a significant CAGR over the forecast period.
 

• Kits and reagents are favoured for their ease of use, enabling healthcare professionals to perform tests with minimal training and ensuring quick turnaround times for results. This convenience is particularly valuable in various healthcare settings, including clinics, hospitals, and remote locations, where immediate diagnosis is crucial for effective patient management.
   
• Moreover, as healthcare systems continue to prioritize rapid diagnostics to improve patient outcomes and streamline workflows, the kits and reagents segment is well-positioned to capitalize on these trends, fostering its growth in the market.
   

Based on technology, the point of care infectious disease testing market is bifurcated into molecular diagnostics, lateral flow immunoassay, agglutination test, flow-through test/immunoconcentration assay, and other technologies. The molecular diagnostics segment is projected to grow at a CAGR of 6.8% by 2032.
 

• Advancements in technology have significantly enhanced the accuracy and speed of molecular diagnostic tests, allowing for rapid and reliable pathogen detection. This is particularly important in infectious disease management, where timely diagnosis can lead to improved patient outcomes and containment of outbreaks.
   
• Additionally, the rising awareness of the importance of early diagnosis in controlling infectious diseases further supports this growth. Moreover, the COVID-19 pandemic has underscored the value of point-of-care molecular diagnostics, leading to greater acceptance and adoption of these technologies across healthcare settings.
   

Based on application, the point of care infectious disease testing market is bifurcated into tropical diseases, liver diseases, respiratory diseases, hospital associated infections, sexual health disorders, and other applications. The respiratory diseases segment is projected to grow at a CAGR of 7% during the forecast period to reach USD 2.4 billion by 2032.
 

• The rising incidence of respiratory infections, particularly those caused by viral pathogens such as influenza and SARS-CoV-2, has significantly heightened the demand for rapid and accurate testing solutions.
   
• For instance, influenza, classified as both a seasonal and pandemic virus by the World Health Organization (WHO), affects up to one billion people each year, primarily during the winter months, making it one of the most prevalent infectious respiratory viruses after the common cold. This widespread impact has led to increased public awareness about respiratory diseases and their transmission, resulting in a greater emphasis on early detection and preventive measures, which further stimulates the demand for point-of-care (POC) testing.
   
• Additionally, government initiatives aimed at enhancing healthcare infrastructure and improving access to testing in both urban and rural settings promote the implementation of efficient diagnostic solutions to effectively combat respiratory illnesses.
   
• Therefore, the combination of rising infection rates and heightened awareness positions the respiratory diseases segment for significant growth in the point-of-care infectious disease testing market.
   

Based on end use, the POC infectious disease testing market is bifurcated into hospitals, diagnostic centers, research and academic institutes, homecare settings, and other end users. The hospitals segment is projected to grow at a CAGR of 6.9% during the forecast period.
 

• The increasing prevalence of infectious diseases, coupled with the need for rapid diagnosis and treatment, drives the adoption of POC testing technologies in hospital settings. These tests provide immediate results, enabling healthcare professionals to make timely decisions and initiate appropriate treatments, which are critical in managing infectious diseases effectively.
   
• Additionally, the growing focus on patient-centered care and the desire to reduce patient waiting times further bolster the demand for POC testing in hospitals. Innovations in POC testing technologies, including enhanced accuracy, ease of use, and integration with electronic health records, also contribute to their rising adoption.
   
• Furthermore, the ongoing emphasis on reducing healthcare costs and improving operational efficiency in hospitals aligns with the advantages offered by POC testing, such as minimizing the need for centralized laboratory testing and streamlining workflow processes.
   
• Therefore, as hospitals continue to prioritize improved patient outcomes and operational efficiency, the market within this segment is poised for substantial growth.
   

North America region accounted for a 46.6% revenue share in 2023 and is expected to experience substantial growth reaching USD 2.7 billion by 2032.
 

• North America features a robust healthcare system equipped with advanced technology and a highly skilled workforce, facilitating the swift adoption of innovative point-of-care infectious disease testing solutions. This strong infrastructure plays a crucial role in propelling overall market growth.
   
• Additionally, increasing health awareness among consumers is fostering a proactive approach to healthcare. Patients are more frequently seeking preventive measures and early diagnostics, which significantly boosts the demand for point-of-care testing services and technologies in the region.
   

The point of care infectious disease testing market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK’s healthcare system is increasingly adopting decentralized healthcare models, highlighting the necessity for testing to occur closer to patients. Point-of-care (POC) testing supports this shift by enabling tests to be performed in various environments, such as clinics, pharmacies, and even patients' homes. This enhanced accessibility not only boosts patient engagement but also alleviates the pressure on centralized laboratory services.
   
• Furthermore, the integration of POC testing with telehealth services is anticipated to further accelerate market growth. Therefore, as telehealth continues to evolve, POC tests can deliver immediate results that enhance virtual consultations, improving the overall efficiency of healthcare delivery and making POC testing solutions more appealing in the region.
   

Japan POC infectious disease testing market is anticipated to witness lucrative growth between 2024 and 2032.
 

• Japan is experiencing a rise in the incidence of infectious diseases, including respiratory infections like tuberculosis (TB) and sexually transmitted infections. For instance, the Japan TB Surveillance Center's Annual Report 2022 reported 11,519 newly confirmed cases of TB, classifying the country as a medium-burden TB nation.
   
• Therefore, this growing number of infections underscores the need for rapid and accurate diagnostics to effectively manage these conditions, thereby propelling demand for point-of-care (POC) testing solutions.
   

The point of care infectious disease testing market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi government is actively investing in healthcare infrastructure and public health initiatives aimed at improving disease detection and management.
   
• This includes efforts to enhance diagnostic capabilities, promote the adoption of innovative technologies, and expand access to healthcare services, all of which are expected to stimulate growth in the market.
   

Point of Care Infectious Disease Testing Market Share

The market is characterized by a competitive landscape with major global companies and smaller to medium-sized firms vying for market share. A central strategy involves the continuous development of innovative testing solutions that enhance diagnostic accuracy and speed. Key industry players drive advancements through substantial investments in research and development to improve testing methodologies and patient accessibility.
 

Strategic alliances, partnerships, and collaborations are essential for strengthening market positions and expanding global reach in response to evolving regulatory standards and increasing demand for rapid POC testing solutions, particularly as the emphasis on decentralized healthcare and the integration of telehealth services grows.
 

Point of Care Infectious Disease Testing Market Companies

Some of the eminent market participants operating in the point of care infectious disease testing industry include:

• Abbott Laboratories
• Becton, Dickinson and Company
• Biomerieux
• Bio-Rad Laboratories
• Cardinal Health
• Chembio Diagnostics
• Danaher Corporation
• F. Hoffmann-La Roche
• OJ-Bio
• QuidelOrtho Corporation
• Siemens Healthineers
• Trinity Biotech
• Trivitron Healthcare
   

Point of Care Infectious Disease Testing Industry News:

• In March 2024, Biomerieux received U.S. FDA 510(k) clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel. This approval gave Biomerieux a competitive advantage in the respiratory infection diagnostics market.
   
• In January 2024, Roche acquired LumiraDx’s point of care technology, significantly strengthening its product portfolio within the POC division. LumiraDx’s portable platform, weighing just 1.1 kg and powered by either a rechargeable battery or mains, offers versatile testing capabilities for infectious diseases, cardiovascular conditions, diabetes, and coagulation disorders, all on a single device. This acquisition enhanced Roche's position in the point of care market by adding this innovative, multi-disease diagnostic solution to its offerings.
   

The point of care infectious disease testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Kits and reagents
• Instruments

Market, By Technology

• Molecular diagnostics
• Lateral flow immunoassay
• Agglutination test
• Flow-through test/immunoconcentration assay
• Other technologies            

Market, By Application

• Tropical diseases
• Liver diseases
• Respiratory diseases
• Hospital associated infections
• Sexual health disorders
• Other applications                       

Market, By End use

• Hospitals
• Diagnostic centers
• Research and academic Institutes
• Homecare settings
• Other end users                

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE